By mid-2026, public markets quality 2026 is no longer the inexpensive compounder sleeve that many family offices still describe in their investment policy. After the 2022 rate shock, a later rerating of mega-cap growth, and years of crowding into the same high-ROE names, quality is a valuation and concentration problem as much as a factor label. This note is general information for families and family offices. It is not a mandate, a trading recommendation, or personalized advice.
Families who built listed-equity books in the 2010s often treated quality as a moral category: low leverage, stable returns on equity, and businesses that compound without drama. By 2025 and into the first half of 2026, the same label often means a crowded sleeve of expensive mega-caps, a large US dollar weight, and an opportunity cost versus cyclicals, value, and smaller companies. Vellum Finance treats the question as a policy problem, not a slogan.
What quality meant before 2022
Before the inflation shock of 2021-2022, quality in public markets had a stable meaning in research and in index construction. Factor indexes that claim to capture durable businesses typically combine high profitability, conservative balance sheets, and stable earnings. The MSCI Quality Indexes are explicit: the quality score rests on return on equity, debt to equity, and earnings variability. That is a rules-based definition, not a private-bank adjective for companies the house happens to like.
In the 2010s that definition overlapped with a market regime. Policy rates in the euro area and in the United States sat at or near the floor for years, so duration was cheap to own and compounders were priced as bond-like instruments with an equity kicker. The OECD finance work on markets and household balance sheets is not a trading manual, yet it is a reminder that cheap money changes which assets look defensive.
Two caveats already sat inside that comfort. First, quality as a factor is not the same as quality as a business: a high ROE can be a temporary mix, buybacks, or a narrow product cycle. Second, when many allocators use the same three screens, the sleeve becomes a crowded trade. The 2010s hid that crowding because the discount rate was falling. Families inherited a vocabulary that sounded like risk control. It was also a duration bet.
The rate shock and the quality rerating through 2026
The 2022-2024 sequence broke that story. When inflation forced a rapid tightening, long-duration cash flows were discounted at a higher rate. Bond-like quality was wrecked in the same way long-dated bonds were wrecked: not because the businesses vanished, but because the price of waiting for distant earnings reset. That was the quality factor rerating in its first, painful direction. The European Central Bank published the path of key rates and the transmission of policy to euro-area financing conditions.
As the hiking cycle peaked and markets priced a plateau rather than an endless rise in rates, those cash flows were bid again. Leadership concentrated in a handful of mega-cap franchises, many US-listed and many tied to capital expenditure on artificial intelligence, cloud, and digital infrastructure. Quality and mega-cap growth were no longer synonyms for boring compounders. They became the market. Passive vehicles that screen for profitability and low leverage still held many of those names, because the screens still passed.
Through 2025 and the first half of 2026, that pattern did not reverse in a neat mean-reversion. Families who waited for quality to become cheap again often watched the same names become a larger share of global market capitalisation. The International Monetary Fund has, across successive Global Financial Stability Reports, described how listed-market risk can concentrate in a small set of issuers and economies. This article does not invent an index level or a price-to-earnings ratio. The structural fact is enough: the sleeve that survived 2022 is more expensive, more crowded, and more dependent on a few balance sheets than the quality book of 2016.
Concentration: when a quality sleeve is a mega-cap bet
Concentration is the operational test that most policy statements skip. A family can hold a quality UCITS, a quality SMA, and a global large-cap tracker, and still own the same handful of issuers three times. Look-through weights, not share-class names, are the only honest book. Mega-cap concentration risk is a single-name, single-sector, and single-currency exposure that the family may already have in private holdings, stock-option wealth, or a founder line.
Quality indexes that weight by the product of a quality score and market capitalisation still inherit the parent index’s size bias. An issuer cap, where a methodology applies one, is a governor, not a diversified portfolio. If the parent is already dominated by a few technology and communication platforms, the quality child can be a slightly cleaner version of the same bet. Direct indexing can carve out names the family already owns. A passive quality ETF cannot.
Supervisors care about this at the product level even when families do not. The European Securities and Markets Authority publishes risk reports that treat liquidity, leverage, and concentration as ordinary UCITS and AIF questions. In France, the Autorité des marchés financiers is the supervisor families should expect on a CIF or investment-firm file when a quality product is sold as defensive. Defensive is a claim about behaviour in a stress, not a claim that the top holdings are small. A family-office look-through should show issuer weight, sector weight, listed versus private overlap, and the share of the book that is in fact a US mega-cap cluster.
What public markets quality 2026 costs now
The cost is not a single multiple that this article will invent. It is three prices that arrive together: valuation, crowding, and the opportunity cost of what the sleeve no longer holds. Families who still hear quality as a synonym for inexpensive safety are paying those prices without naming them.
Valuation, crowding, and what the sleeve no longer owns
Valuation is the obvious cost. A high-ROE, low-leverage franchise can still be a poor holding if the entry price assumes that the ROE is perpetual and that the discount rate never rises again. When a factor becomes a product, inflows bid the same screens, and the screens then look even more like quality because the winners get larger. Crowding is the second cost: if the exit is correlated, the sleeve can fall together even if the businesses remain sound. That is not an argument against owning good companies. It is an argument against treating the label as a free hedge.
The third cost is opportunity. Cyclicals, value, small-cap, and some non-US markets spent parts of 2022-2026 cheaper relative to the crowded quality names, in the structural sense that capital preferred the familiar mega-caps. A family that defined its entire listed book as quality missed that relative cheapness by construction. Relative cheapness is not a guarantee of catch-up. It is a budget item: how much of the equity policy is allowed to sit outside the quality sleeve. Adjacent reading sits in Vellum’s note on global stock-market insights and corporate profitability in 2026.
Currency for euro families and the rest of the book
For a euro-based family, quality in public markets is often a dollar decision wearing an equity label. Mega-cap leadership has been heavily US-listed. An unhedged quality sleeve therefore embeds a euro-dollar view, a US-policy view, and a sector view. Hedging the currency changes the return path and the cash need for variation margin or forward rolls. Leaving it unhedged is a choice, not a default. The ECB’s policy path and the euro’s purchasing power belong in the same file as the equity sleeve.
The rest of the book matters. If the family already has dollar operating cash, US private equity, and a founder line in a listed US platform, adding a quality UCITS that repeats those names is not diversification. If the family is euro-heavy in private operating companies and real estate, a listed quality sleeve can be a useful liquid diversifier, provided the valuation and concentration budgets are written down. Currency, listed-private overlap, and liquidity should appear in the same investment policy paragraph, not as afterthoughts on a factsheet.
How a family office should budget quality
Quality belongs in a family office equity policy as a sleeve with limits, not as a personality trait of the portfolio. The policy should name what quality means in that office: a factor definition (ROE, leverage, earnings stability), a fundamental shortlist, or a simple compounder narrative. Mixing the three without saying so produces a book that cannot be rebalanced, because nobody can say what is overweight.
A valuation budget is a ceiling on how much the family will pay, in terms the office can actually measure, before it trims. A concentration budget is a ceiling on issuer, sector, country, and listed-private overlap. Neither budget is a trading rule for next week. Both are governance: who measures, how often, and what happens when the ceiling is hit. Rebalancing is the mechanism. Without a written trigger, quality becomes a one-way allocation that only grows.
Implementation is a separate choice. Passive quality funds are cheap, rules-based, and honest about inheriting size. Active quality can refuse a name or a price, or hug the crowded benchmark. Direct indexing listed equities lets the family hold a custom quality universe, harvest tax lots where the jurisdiction allows, and exclude names already owned privately or in a founder line. Each path can be right. None of them is quality by itself. For how product shelves distort that choice, see the 2026 note on open architecture versus in-house funds. Advice and look-through sit on the Vellum Finance services map.
Direct indexing, active selection, and the rebalancing clock
Direct indexing is useful when the family’s tax lot, exclusion list, or overlap with private assets is the real constraint. It is less useful when the family simply wants a cheap factor and has no exclusions. Active selection is useful when the office can underwrite a different definition of quality than the index, and can fire the manager when that definition is not delivered. It is expensive theatre when the active book is the index plus a higher fee. A quarterly look-through of issuer weights and an annual rewrite of what quality means in the policy are enough for most families. Daily tinkering is a trading note. This article is not one.
Vellum is a fee-only multi-family office. The family pays for the policy, the look-through, and the second pair of eyes, not for a quality product. That does not make every quality holding a mistake. It makes the holding a line in a budget: how much, at what price, with what overlap, in which currency, and with which replacement rule.
Conclusion
Quality in the 2010s meant low leverage, stable ROE, and compounders that behaved like bonds with growth. The 2022 rate shock wrecked that duration story. The later rerating, concentrated in mega-cap leadership and amplified by AI-related capital expenditure, rebuilt quality as an expensive, crowded sleeve. Public markets quality 2026 therefore costs valuation, concentration, opportunity, and, for euro families, currency. A family office should keep quality as a policy sleeve with a valuation budget, a concentration budget, and a rebalancing clock, implemented through passive, active, or direct indexing on purpose. The label is not a hedge. The budget is.
Discretion. Stability. Prosperity.
Team Vellum
A team of passionate professionals who combine their expertise to bring knowledge through Vellum Finance & Patrimoine blog articles. Each member writes about their own field of expertise, cross referencing with our colleagues own fields to ensure the highest quality of information possible in all our content.
